Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 261-270 of 603 for hematology

Edit search filters
  1. A Study In Subjects With Relapsed And Refractory Multiple Myeloma Receiving Carfilzomib In Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW)

    Scottsdale/Phoenix, AZ

  2. Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

    Rochester, MN

  3. Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

    Jacksonville, FL, Rochester, MN

  4. A Study To Assess The Effectiveness And Safety Of Ublituximab In Combination With Umbralisib And Venetoclax (U2-V) Compared To Ublituximab And Umbralisib (U2) In Subjects With Chronic Lymphocytic Leukemia (CLL)

    Jacksonville, FL, Rochester, MN

  5. Ibrutinib In Treating Minimal Residual Disease In Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy

    Jacksonville, FL

  6. A Trial Of TTI-621 For Patients With Hematologic Malignancies And Selected Solid Tumors

    Jacksonville, FL, Rochester, MN

  7. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

    Scottsdale/Phoenix, AZ

  8. Atezolizumab Immunotherapy In Patients With Advanced NSCLC (AJCC 7th Edition)

    Scottsdale/Phoenix, AZ

  9. A Study To Evaluate CB-839 HCl In Combination With Carfilzomib And Dexamethasone In Treating Patients With Recurrent Or Refractory Multiple Myeloma

    Rochester, MN

  10. Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, And Filgrastim In Treating Younger Patients With Relapsed Or Refractory Acute Myeloid Leukemia

    Rochester, MN

.

Mayo Clinic Footer